BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 27542119)

  • 1. QSAR modeling to design selective histone deacetylase 8 (HDAC8) inhibitors.
    Cao GP; Thangapandian S; Son M; Kumar R; Choi YJ; Kim Y; Kwon YJ; Kim HH; Suh JK; Lee KW
    Arch Pharm Res; 2016 Oct; 39(10):1356-1369. PubMed ID: 27542119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A lazy learning-based QSAR classification study for screening potential histone deacetylase 8 (HDAC8) inhibitors.
    Cao GP; Arooj M; Thangapandian S; Park C; Arulalapperumal V; Kim Y; Kwon YJ; Kim HH; Suh JK; Lee KW
    SAR QSAR Environ Res; 2015; 26(5):397-420. PubMed ID: 25986171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of novel potential selective HDAC8 inhibitors by combine ligand-based, structure-based virtual screening and in-vitro biological evaluation.
    Debnath S; Debnath T; Bhaumik S; Majumdar S; Kalle AM; Aparna V
    Sci Rep; 2019 Nov; 9(1):17174. PubMed ID: 31748509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ligand and structure based pharmacophore modeling to facilitate novel histone deacetylase 8 inhibitor design.
    Thangapandian S; John S; Sakkiah S; Lee KW
    Eur J Med Chem; 2010 Oct; 45(10):4409-17. PubMed ID: 20656379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Docking and QSAR Studies of Aryl-valproic Acid Derivatives to Identify Antiproliferative Agents Targeting the HDAC8.
    Martínez-Pacheco H; Ramírez-Galicia G; Vergara-Arias M; Gertsch J; Fragoso-Vazquez JM; Mendez-Luna D; Abujamra AL; Cristina CL; Cecilia RM; Mendoza-Lujambio I; Correa-Basurto J
    Anticancer Agents Med Chem; 2017; 17(7):927-940. PubMed ID: 27774878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An insight into selective and potent inhibition of histone deacetylase 8 through induced-fit docking, pharmacophore modeling and QSAR studies.
    Kashyap K; Kakkar R
    J Biomol Struct Dyn; 2020 Jan; 38(1):48-65. PubMed ID: 30633630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diverse classes of HDAC8 inhibitors: in search of molecular fingerprints that regulate activity.
    Amin SA; Adhikari N; Jha T
    Future Med Chem; 2018 Jul; 10(13):1589-1602. PubMed ID: 29953251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel inhibitors of human histone deacetylase (HDAC) identified by QSAR modeling of known inhibitors, virtual screening, and experimental validation.
    Tang H; Wang XS; Huang XP; Roth BL; Butler KV; Kozikowski AP; Jung M; Tropsha A
    J Chem Inf Model; 2009 Feb; 49(2):461-76. PubMed ID: 19182860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis, and biological activity of NCC149 derivatives as histone deacetylase 8-selective inhibitors.
    Suzuki T; Muto N; Bando M; Itoh Y; Masaki A; Ri M; Ota Y; Nakagawa H; Iida S; Shirahige K; Miyata N
    ChemMedChem; 2014 Mar; 9(3):657-64. PubMed ID: 24403121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Docking of hydroxamic acids into HDAC1 and HDAC8: a rationalization of activity trends and selectivities.
    Ortore G; Di Colo F; Martinelli A
    J Chem Inf Model; 2009 Dec; 49(12):2774-85. PubMed ID: 19947584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histone deacetylase 8 (HDAC8) and its inhibitors with selectivity to other isoforms: An overview.
    Banerjee S; Adhikari N; Amin SA; Jha T
    Eur J Med Chem; 2019 Feb; 164():214-240. PubMed ID: 30594678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynamic structure-based pharmacophore model development: a new and effective addition in the histone deacetylase 8 (HDAC8) inhibitor discovery.
    Thangapandian S; John S; Lee Y; Kim S; Lee KW
    Int J Mol Sci; 2011; 12(12):9440-62. PubMed ID: 22272142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Docking-enabled pharmacophore model for histone deacetylase 8 inhibitors and its application in anti-cancer drug discovery.
    Thangapandian S; John S; Sakkiah S; Lee KW
    J Mol Graph Model; 2010 Nov; 29(3):382-95. PubMed ID: 20870437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rational design of selective HDAC2 inhibitors for liver cancer treatment: computational insights into the selectivity mechanism through molecular dynamics simulations and QM/MM calculations.
    Yang Y; Hu B; Yang Y; Gong K; Wang H; Guo Q; Tang X; Li Y; Wang J
    Phys Chem Chem Phys; 2021 Aug; 23(32):17576-17590. PubMed ID: 34369509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Covalent inhibition of histone deacetylase 8 by 3,4-dihydro-2H-pyrimido[1,2-c][1,3]benzothiazin-6-imine.
    Muth M; Jänsch N; Kopranovic A; Krämer A; Wössner N; Jung M; Kirschhöfer F; Brenner-Weiß G; Meyer-Almes FJ
    Biochim Biophys Acta Gen Subj; 2019 Mar; 1863(3):577-585. PubMed ID: 30611847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-Based Design and Biological Characterization of Selective Histone Deacetylase 8 (HDAC8) Inhibitors with Anti-Neuroblastoma Activity.
    Heimburg T; Kolbinger FR; Zeyen P; Ghazy E; Herp D; Schmidtkunz K; Melesina J; Shaik TB; Erdmann F; Schmidt M; Romier C; Robaa D; Witt O; Oehme I; Jung M; Sippl W
    J Med Chem; 2017 Dec; 60(24):10188-10204. PubMed ID: 29190092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Binding Free Energy (BFE) Calculations and Quantitative Structure-Activity Relationship (QSAR) Analysis of
    Simoben CV; Ghazy E; Zeyen P; Darwish S; Schmidt M; Romier C; Robaa D; Sippl W
    Molecules; 2021 Apr; 26(9):. PubMed ID: 33925246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of Histone Deacetylase 8 (HDAC8) Selective Inhibition Reveals Specific Active Site Structural and Functional Determinants.
    Marek M; Shaik TB; Heimburg T; Chakrabarti A; Lancelot J; Ramos-Morales E; Da Veiga C; Kalinin D; Melesina J; Robaa D; Schmidtkunz K; Suzuki T; Holl R; Ennifar E; Pierce RJ; Jung M; Sippl W; Romier C
    J Med Chem; 2018 Nov; 61(22):10000-10016. PubMed ID: 30347148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of Conformationally Constrained Benzanilide Scaffolds for Potent and Selective HDAC8 Targeting.
    Hassan MM; Israelian J; Nawar N; Ganda G; Manaswiyoungkul P; Raouf YS; Armstrong D; Sedighi A; Olaoye OO; Erdogan F; Cabral AD; Angeles F; Altintas R; de Araujo ED; Gunning PT
    J Med Chem; 2020 Aug; 63(15):8634-8648. PubMed ID: 32672458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Computational identification of novel histone deacetylase inhibitors by docking based QSAR.
    Nair SB; Teli MK; Pradeep H; Rajanikant GK
    Comput Biol Med; 2012 Jun; 42(6):697-705. PubMed ID: 22521374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.